Terms: = Skin cancer AND PR, PGR, progesterone receptor AND Clinical Outcome
16 results:
1. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
2. Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT).
Hiratsuka J; Kamitani N; Tanaka R; Tokiya R; Yoden E; Sakurai Y; Suzuki M
J Radiat Res; 2020 Nov; 61(6):945-951. PubMed ID: 32990318
[TBL] [Abstract] [Full Text] [Related]
3. Dabrafenib Therapy in 30 Patients with Melanoma Metastatic to the Brain: a Single-centre Controlled Retrospective Study in Hungary.
Gorka E; Fabó D; Gézsi A; Czirbesz K; Fedorcsák I; Liszkay G
Pathol Oncol Res; 2018 Apr; 24(2):401-406. PubMed ID: 28567600
[TBL] [Abstract] [Full Text] [Related]
4. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM
Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626
[TBL] [Abstract] [Full Text] [Related]
5. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Ridolfi L; Petrini M; Granato AM; Gentilcore G; Simeone E; Ascierto PA; Pancisi E; Ancarani V; Fiammenghi L; Guidoboni M; de Rosa F; Valmorri L; Scarpi E; Nicoletti SV; Baravelli S; Riccobon A; Ridolfi R
J Transl Med; 2013 May; 11():135. PubMed ID: 23725550
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
Odunsi K; Matsuzaki J; Karbach J; Neumann A; Mhawech-Fauceglia P; Miller A; Beck A; Morrison CD; Ritter G; Godoy H; Lele S; duPont N; Edwards R; Shrikant P; Old LJ; Gnjatic S; Jäger E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5797-802. PubMed ID: 22454499
[TBL] [Abstract] [Full Text] [Related]
7. T4b breast masses: a retrospective review of 12 cases presenting to a metropolitan tertiary care center.
Downing S; Akinrinlola A; Siram SM; DeWitty RL; Paul H; Dawson K; Frederick WA
J Natl Med Assoc; 2011 Aug; 103(8):757-61. PubMed ID: 22046854
[TBL] [Abstract] [Full Text] [Related]
8. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Dragovich T; McCoy S; Fenoglio-Preiser CM; Wang J; Benedetti JK; Baker AF; Hackett CB; Urba SG; Zaner KS; Blanke CD; Abbruzzese JL
J Clin Oncol; 2006 Oct; 24(30):4922-7. PubMed ID: 17050876
[TBL] [Abstract] [Full Text] [Related]
9. [Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Tendo M; Nakata B; Nishino H; Inoue M; Kosaka K; Amano R; Yamada N; Hirakawa K
Gan To Kagaku Ryoho; 2005 Jun; 32(6):795-8. PubMed ID: 15984518
[TBL] [Abstract] [Full Text] [Related]
10. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
[TBL] [Abstract] [Full Text] [Related]
11. Sebaceous carcinoma of the eyelids: frequent expression of c-erbB-2 oncoprotein.
Cho KJ; Khang SK; Koh JS; Chung JH; Lee SS
J Korean Med Sci; 2000 Oct; 15(5):545-50. PubMed ID: 11068992
[TBL] [Abstract] [Full Text] [Related]
12. Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
Meijer-van Gelder ME; Look MP; Bolt-de Vries J; Peters HA; Klijn JG; Foekens JA
J Clin Oncol; 1999 May; 17(5):1449-57. PubMed ID: 10334530
[TBL] [Abstract] [Full Text] [Related]
13. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract] [Full Text] [Related]
14. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R
Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511
[TBL] [Abstract] [Full Text] [Related]
15. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract] [Full Text] [Related]
16. Exacerbation of metastatic disease shortly after administration of tamoxifen in ER negative advanced breast carcinoma. A case report.
Cocconi G; Boni C; Naldi N; Nizzoli R; Bozzetti C
Tumori; 1989 Dec; 75(6):566-9. PubMed ID: 2617702
[TBL] [Abstract] [Full Text] [Related]
